HBDA Quarterly Newsletter

Summer Edition 2020 | Rick Dinkins, Chairman
Volume 46 | Vicki Jackson, Executive Director

Table of Contents

Staff

Executive Director
Vicki Jackson
Consumer Relations Manager
Amanda Jennings

HBDA
Hemophilia and Bleeding Disorders of Alabama, Inc.

Board Members

Rick Dinkins - Chairman
Jared McLaughlin - Treasurer
Van Rushton

Brian Ward - Past President
Chris Blair - Past President

Words from the Chair



As I write this, we are all anticipating what is to come with respect to COVID 19 and the next several months. School openings are just around the corner, in some form or fashion, and we are wondering if college football is going to happen. We see the CORONA numbers every day and are not sure what it REALLY means and how we press on with our lives.

The HBDA staff and Board have been following all of this and have adjusted our day to day operations to reflect these changing times. Our "virtual" Annual Meeting/events are ongoing via Zoom and will continue till late August or early September. Fall planning is underway to include the Annual Golfing fundraiser in November and Family Camp in October. That said, we are at the mercy of state guidelines and how they affect the Children's Harbor venue for final resolution, but we continue to plan as if it is going to happen. Stay tuned for more details.

As mentioned, the month of August is filled with Zoom and web events and they seem to be going well so far. We are seeing pretty good participation and the sponsors seem pleased with the results and patient interaction. For more details on our web events, give the HBDA office a call or check out the web site for more information. While visiting our website, please take a look at the Virtual Annual Meeting Page for resources from our sponsors.

These are trying times for all of us. Our way of life has certainly changed… now it's, where's my phone and where's my mask! That said, we are all much better off than many other people in this world and for that, we should be grateful. Let's all do our part to "Stay Safe" and know that this too will pass. Take care….

Rick Dinkins
Chairman, HBDA

Stay Well and Wash Your Hands!

Save the Date

For HBDA's

Family Educational Weekend

Mark your Calendars for

October 23 – 25, 2020

Keep an eye out for more information coming to your inbox soon!

This will be a wonderful weekend full of fellowship and education!

HBDA

Hemophilia and Bleeding Disorders of Alabama, Inc.



CHILDREN'S HARBOR

Hemdifferently

Exploring the science behind gene therapy research

Gene therapy research has the potential to bring an entirely new option to people with specific genetic conditions. Many gene therapies are in clinical trials to evaluate the possible risks and benefits for a range of conditions, including hemophilia. HemDifferently is here with gene therapy education, providing accurate information in a way you can understand.

Let's explore gene therapy together at **HemDifferently.com**

No gene therapies for hemophilia have been approved for use or determined to be safe or effective.

BIOMARIN

HBDA 2020 Golf Tournament

Attention All Golfers!
Don't "fore-get" to register
for HBDA's 2020 Golf Tournament!

Registration - 11:00 AM
Lunch - 12:00 PM
Tee Off - 1:00 PM

Robert Trent Jones Golf Trail
Capitol Hill

For more information, please contact us at hbdaevents@gmail.com or call us at 334-478-7822

HBDA's 12th Annual "Tee It Up for Hemophilia" Golf Tournament

November 13, 2020

at one of the jewels in the River Region's crown,
The Robert Trent Jones Golf Trail at Capitol Hill in Prattville, Alabama.

Join us in this fun filled day of golf and probably some good-natured ribbing between our golfers.

HBDA's tournament is so much more than just golf!

You will have a chance to win fabulous gifts, enjoy an afternoon of spending time with your friends, a delectable lunch, and awards. To top the day off, we will have a fabulous wrap up cocktail soiree, and who knows, maybe even say hello to a celebrity or two!

Stay tuned for more information from HBDA regarding this event!

HBDA
Hemophilia and Bleeding Disorders of Alabama, Inc.

BIG NEWS ABOUT BOMBARDIER BLOOD!

It's official!

The documentary of Chris Bombardier's attempt to be the first person with severe hemophilia to summit Mount Everest is available for pre-order!

Pre-order the film today to get Bombardier Blood and #hemophilia on the front page of iTunes: bit.ly/preorderbb

20% of proceeds support Save One Life (Tag @saveonelife)

Follow Bombardier Blood (tag: @bombardierblood) to be the first to know where else you can watch the film when it's released worldwide, August 18th!

SHARE this post and BOMBARDIER BLOOD with friends and family, too!

#bombardierblood #saveonelife #hemophilia #bleedingdisorders

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. HEMLIBRA may cause serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including thrombotic microangiopathy (TMA), and blood clots (thrombotic events). If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

Please see Brief Summary of Medication Guide on following page for Important Safety Information, including **Serious Side Effects**.

HEMLIBRA®
emicizumab-kxwh
injection for subcutaneous use | 150 mg/mL

Medication Guide
HEMLIBRA® (hem-lee-bruh) (emicizumab-kxwh) injection, for subcutaneous use

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII (FVIII) and the recommended dose and schedule to use for breakthrough bleed treatment.

HEMLIBRA may cause the following serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including:

- **Thrombotic microangiopathy (TMA).** This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the following signs or symptoms during or after treatment with HEMLIBRA:
  - confusion
  - weakness
  - swelling of arms and legs
  - yellowing of skin and eyes
  - stomach (abdomen) or back pain
  - nausea or vomiting
  - feeling sick
  - decreased urination
- **Blood clots (thrombotic events).** Blood clots may form in blood vessels in your arm, leg, lung, or head. Get medical help right away if you have any of these signs or symptoms of blood clots during or after treatment with HEMLIBRA:
  - swelling in arms or legs
  - pain or redness in your arms or legs
  - shortness of breath
  - chest pain or tightness
  - fast heart rate
  - cough up blood
  - feel faint
  - headache
  - numbness in your face
  - eye pain or swelling
  - trouble seeing

If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

See "**What are the possible side effects of HEMLIBRA?**" for more information about side effects.

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

Hemophilia A is a bleeding condition people can be born with where a missing or faulty blood clotting factor (factor VIII) prevents blood from clotting normally.

HEMLIBRA is a therapeutic antibody that bridges clotting factors to help your blood clot.

Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you:

- are pregnant or plan to become pregnant. It is not known if HEMLIBRA may harm your unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with HEMLIBRA.
- are breastfeeding or plan to breastfeed. It is not known if HEMLIBRA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I use HEMLIBRA?

See the detailed "Instructions for Use" that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

- Use HEMLIBRA exactly as prescribed by your healthcare provider.
- **Stop (discontinue) prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.**
- **You may continue prophylactic use of FVIII for the first week of HEMLIBRA prophylaxis.**
- HEMLIBRA is given as an injection under your skin (subcutaneous injection) by you or a caregiver.
- Your healthcare provider should show you or your caregiver how to prepare, measure, and inject your dose of HEMLIBRA before you inject yourself for the first time.
- Do not attempt to inject yourself or another person unless you have been taught how to do so by a healthcare provider.
- Your healthcare provider will prescribe your dose based on your weight. If your weight changes, tell your healthcare provider.
- You will receive HEMLIBRA 1 time a week for the first four weeks. Then you will receive a maintenance dose as prescribed by your healthcare provider.
- If you miss a dose of HEMLIBRA on your scheduled day, you should give the dose as soon as you remember. You must give the missed dose as soon as possible before the next scheduled dose, and then continue with your normal dosing schedule. **Do not** give two doses on the same day to make up for a missed dose.
- HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.

What are the possible side effects of HEMLIBRA?

- See "**What is the most important information I should know about HEMLIBRA?**"

The most common side effects of HEMLIBRA include:

- redness, tenderness, warmth, or itching at the site of injection
- headache
- joint pain

These are not all of the possible side effects of HEMLIBRA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store HEMLIBRA?

- Store HEMLIBRA in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze.
- Store HEMLIBRA in the original carton to protect the vials from light.
- Do not shake HEMLIBRA.
- If needed, unopened vials of HEMLIBRA can be stored out of the refrigerator and then returned to the refrigerator. HEMLIBRA should not be stored out of the refrigerator for more than a total of 7 days or at a temperature greater than 86°F (30°C).
- After HEMLIBRA is transferred from the vial to the syringe, HEMLIBRA should be used right away.
- Throw away (dispose of) any unused HEMLIBRA left in the vial.

Keep HEMLIBRA and all medicines out of the reach of children.

General information about the safe and effective use of HEMLIBRA.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use HEMLIBRA for a condition for which it was not prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about HEMLIBRA that is written for health professionals.

What are the ingredients in HEMLIBRA?

Active ingredient: emicizumab-kxwh

Inactive ingredients: L-arginine, L-histidine, poloxamer 188, and L-aspartic acid.

Manufactured by: Genentech, Inc., A Member of the Roche Group,
1 DNA Way, South San Francisco, CA 94080-4990
U.S. License No. 1048

For more information, go to www.HEMLIBRA.com or call 1-866-HEMLIBRA.
This Medication Guide has been approved by the U.S. Food and Drug Administration
Revised: 10/2018

HEMLIBRA®
emicizumab-kxwh
injection for subcutaneous use
150 mg/mL

Genentech
A Member of the Roche Group

At Pfizer Hemophilia, we have always been deeply committed to you and to listening to what you have to say. Over the years, what you've shared with us has proven invaluable. The events we sponsor, the technology we develop, and the educational materials we create are all designed in response to the requests, needs, and desires of the hemophilia community.

We are grateful for having the chance to partner with you.

—Your Pfizer Hemophilia Team

PP-HEM-USA-1120-01

Printed in USA/November 2018

Emotional Wellness as a Mature Adult:

Discussing the Unique Challenges of Living With Hemophilia

For more information, visit b2byourvoice.com to download *Learn from Experience: A Guide for Mature Adults.*

This content is brought to you by Pfizer.

How Hemophilia Affects Mature Adults

Mature adults may look back and recognize how living with hemophilia has influenced who they are today. Persevering through the challenges of being a child diagnosed with hemophilia when less was known about the condition, and navigating the issues of being a young adult with a bleeding condition can shape one's perspective. Knowledge and wisdom are some of the benefits that accrue with age, but along with these can also come additional health concerns such as high blood pressure, diabetes, and arthritis; depression and stress; and financial planning and retirement concerns. For those who have lived with hemophilia for many decades, the task of managing these concerns of older age may seem to be less important. However, there are some key points to keep in mind when addressing the effect hemophilia can have on mental health.

The Risk of Clinical Depression

Mature adults living with hemophilia typically have experienced substantial challenges related to their disease throughout their lives. In some instances, hardships may contribute to the development of clinical depression, which is more common among people living with hemophilia than the general population. The results from one study conducted at a hemophilia treatment center showed that 37% of a sample of patients met the criteria for depression. Of that 37%, 20% had moderate to severe symptoms, and 66% reported having functional impairment due to their depressive symptoms.[1] The authors of the study concluded that the comprehensive care of adults with hemophilia should include depression screening for the potential to improve overall health outcomes.[1]

Education and support for people living with bleeding disorders and their families is one component of managing psychological wellness. Having control over life decisions and self-advocacy can also be important. For some living with hemophilia, past experiences may serve as a motivator to continue to work toward personal objectives. Others may find the journey more difficult to navigate. Self-help seminars and support groups are some of the resources that may help adults set and attain realistic goals.

> "[A reminder to] older adults that there is always somewhere to turn, even in times of immense hardship. All you need to do is ask, and you should never feel ashamed for doing so."
>
> — Judy Bagato
>
> RN, BSN, Hemophilia Specialist

Finding Support for Complex Issues

For people who acquired human immunodeficiency virus (HIV) and/or hepatitis C (HCV) from virally contaminated blood products, there may be feelings of anger and resentment. The adversity caused by a lack of family or social support during younger years or changes later in life, such as changes in one's capacity for employment or altered family dynamics, may also contribute to these feelings. Learning effective ways to cope with the stresses of living with hemophilia in older age may help an individual to be resilient to these challenges. If you are experiencing stress that is affecting your day-to-day outlook, it is important to seek help. Reach out to your treatment team to discuss your situation and learn about what help and support may be available.

Reference: 1. Iannone M, Pennick L, Tom A, et al. Prevalence of depression in adults with haemophilia. *Haemophilia.* 2012;18:868-874. doi: 10.1111/j.1365-2516.2012.02863.x.

PATIENT AFFAIRS LIAISONS

Patient Affairs Liaisons are Pfizer employees who are dedicated solely to providing support to the community. Your Pfizer Patient Affairs Liaison is available to help you access the support and information you need. To find your Patient Affairs Liaison, go to hemophiliavillage.com/support/patient-affairs-liaison-finder or call Pfizer Hemophilia Connect at 1.844.989.HEMO (4366).

PP-HEM-USA-1237

September 2019

Pfizer

CLOT Line Assistance Program

Members:

In this unprecedented time, please remember that we are here for you!

If you have been affected by COVID-19, or if you need assistance purchasing school supplies for your kids, please reach out to us.

Virtual Annual Meeting Series

Date of Presentation:	Company Presenting:	Time of Presentation:
July 23, 2020	Octapharma	7:00 - 8:30 PM
July 28, 2020	Hemophilia Preferred Care	6:30 - 7:30 PM
July 29, 2020	Aptevo	7:00 - 8:30 PM
July 30, 2020	Paragon Healthcare	6:30 - 7:30 PM
August 4, 2020	Takeda	7:00 - 8:30 PM
August 5, 2020	DrugCo Pharmacy	6:30 - 7:30 PM
August 6, 2020	Sanofi Genzyme	7:00 - 8:30 PM
August 18. 2020	Bayer	7:00 - 8:30 PM
August 19, 2020	First Choice Home Infusion	6:30 - 7:30 PM
August 25, 2020	Pfizer	7:00 - 8:30 PM
August 26, 2020	Accredo	6:30 - 7:30 PM
September 1, 2020	CSL Behring	7:00 - 8:30 PM

When it comes to your hemophilia A treatment

Move beyond the threshold[a]

A simple switch to Esperoct® can give you high factor levels for longer.[b]

Extend half-life beyond the standard

22-hour average half-life in adults[c]

High factor levels in adults and adolescents

At or above 3% for 100% of the time[a,d]

At or above 5% for 90% of the time[a,e]

Flexible on the go[c]

The only extended half-life product with stability up to 104°F[f]

[a]Trough level goal is 1% for prophylaxis.
[b]Compared with standard half-life products.
[c]Data shown are from 42 adults who received a pharmacokinetic (PK) assessment around the first Esperoct® 50 IU/kg dose.
[d]Data shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL.
[e]Steady-state FVIII activity levels were estimated in 143 adults and adolescents using PK modeling.
[f]For up to 3 months.

What is Esperoct®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

- Esperoct® is not used to treat von Willebrand Disease

IMPORTANT SAFETY INFORMATION

Who should not use Esperoct®?

- You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins

What is the most important information I need to know about Esperoct®?

- **Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center**
- **Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as:** hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

What should I tell my healthcare provider before using Esperoct®?

- Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
- Your body can make antibodies called "inhibitors" against Esperoct®, which may stop Esperoct® from working properly. **Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®**

What are the possible side effects of Esperoct®?

- Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Please see Brief Summary of Prescribing Information on the following pages.

Discover more at **Esperoct.com.**

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

esperoct®
antihemophilic factor (recombinant), glycopegylated-exei

esperoct®

antihemophilic factor (recombinant), glycopegylated-exei

Brief Summary information about ESPEROCT® [antihemophilic Factor (recombinant), glycopegylated-exei]

This information is not comprehensive.

- Talk to your healthcare provider or pharmacist
- Visit www.novo-pi.com/esperoct.pdf to obtain FDA-approved product labeling
- Call 1-800-727-6500

Patient Information

ESPEROCT®
[antihemophilic factor (recombinant), glycopegylated-exei]

Read the Patient Information and the Instructions For Use that come with ESPEROCT® before you start taking this medicine and each time you get a refill. There may be new information.

This Patient Information does not take the place of talking with your healthcare provider about your medical condition or treatment. If you have questions about ESPEROCT® after reading this information, ask your healthcare provider.

What is the most important information I need to know about ESPEROCT®?

Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center.

You must carefully follow your healthcare provider's instructions regarding the dose and schedule for infusing ESPEROCT® so that your treatment will work best for you.

What is ESPEROCT®?

ESPEROCT® is an injectable medicine used to replace clotting Factor VIII that is missing in patients with hemophilia A. Hemophilia A is an inherited bleeding disorder in all age groups that prevents blood from clotting normally.

ESPEROCT® is used to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A.

Your healthcare provider may give you ESPEROCT® when you have surgery.

Who should not use ESPEROCT®?

You should not use ESPEROCT® if you

- are allergic to Factor VIII or any of the other ingredients of ESPEROCT®
- if you are allergic to hamster proteins

If you are not sure, talk to your healthcare provider before using this medicine.

Tell your healthcare provider if you are pregnant or nursing because ESPEROCT® might not be right for you.

What should I tell my healthcare provider before I use ESPEROCT®?

You should tell your healthcare provider if you:

- Have or have had any medical conditions.
- Take any medicines, including non-prescription medicines and dietary supplements.
- Are nursing.
- Are pregnant or planning to become pregnant.
- Have been told that you have inhibitors to Factor VIII.

How should I use ESPEROCT®?

Treatment with ESPEROCT® should be started by a healthcare provider who is experienced in the care of patients with hemophilia A.

ESPEROCT® is given as an infusion into the vein.

You may infuse ESPEROCT® at a hemophilia treatment center, at your healthcare provider's office or in your home. You should be trained on how to do infusions by your hemophilia treatment center or healthcare provider. Many people with hemophilia A learn to infuse the medicine by themselves or with the help of a family member.

Your healthcare provider will tell you how much ESPEROCT® to use based on your weight, the severity of your hemophilia A, and where you are bleeding. Your dose will be calculated in international units, IU.

Call your healthcare provider right away if your bleeding does not stop after taking ESPEROCT®.

If your bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors. This should be checked by your healthcare provider. You might need a higher dose of ESPEROCT® or even a different product to control bleeding. Do not increase the total dose of ESPEROCT® to control your bleeding without consulting your healthcare provider.

Use in children

ESPEROCT® can be used in children. Your healthcare provider will decide the dose of ESPEROCT® you will receive.

If you forget to use ESPEROCT®

If you forget a dose, infuse the missed dose when you discover the mistake. Do not infuse a double dose to make up for a forgotten dose. Proceed with the next infusions as scheduled and continue as advised by your healthcare provider.

If you stop using ESPEROCT®

Do not stop using ESPEROCT® without consulting your healthcare provider.

If you have any further questions on the use of this product, ask your healthcare provider.

What if I take too much ESPEROCT®?

Always take ESPEROCT® exactly as your healthcare provider has told you. You should check with your healthcare provider if you are not sure. If you infuse more ESPEROCT® than recommended, tell your healthcare provider as soon as possible.

What are the possible side effects of ESPEROCT®?

Common Side Effects Include:

- rash or itching
- swelling, pain, rash or redness at the location of infusion

Other Possible Side Effects:

You could have an allergic reaction to coagulation Factor VIII products. **Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as:** hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face.

Your body can also make antibodies called "inhibitors" against ESPEROCT®, which may stop ESPEROCT® from working properly. Your healthcare provider may need to test your blood for inhibitors from time to time.

These are not all of the possible side effects from ESPEROCT®. Ask your healthcare provider for more information. You are encouraged to report side effects to FDA at 1-800-FDA-1088.

Tell your healthcare provider about any side effect that bothers you or that does not go away.

What are the ESPEROCT® dosage strengths?

ESPEROCT® comes in five different dosage strengths. The actual number of international units (IU) of Factor VIII in the vial will be imprinted on the label and on the box. The five different strengths are as follows:

Cap Color Indicator	Nominal Strength
Red	500 IU per vial
Green	1000 IU per vial
Gray	1500 IU per vial
Yellow	2000 IU per vial
Black	3000 IU per vial

Always check the actual dosage strength printed on the label to make sure you are using the strength prescribed by your healthcare provider.

How should I store ESPEROCT®?

Prior to Reconstitution (mixing the dry powder in the vial with the diluent):

Protect from light. Do not freeze ESPEROCT®.

ESPEROCT® can be stored in refrigeration at 36°F to 46°F (2°C to 8°C) for up to 30 months from the date of manufacture until the expiration date stated on the label.

ESPEROCT® may be stored at room temperature (not to exceed 86°F/30°C), for up to 12 months within the 30-month time period. Record the date when the product was removed from the refrigerator. The total time of storage at room temperature should not exceed 12 months. Do not return the product to the refrigerator.

Do not use this medicine after the expiration date which is on the outer carton and the vial. The expiration date refers to the last day of that month.

After Reconstitution:

The reconstituted (the final product once the powder is mixed with the diluent) ESPEROCT® should appear clear and colorless without visible particles.

The reconstituted ESPEROCT® should be used immediately.

If you cannot use the reconstituted ESPEROCT® immediately, it must be used within 4 hours when stored at or below 86°F (30°C) or within 24 hours when stored in a refrigerator at 36°F to 46°F (2°C to 8°C). Store the reconstituted product in the vial.

Keep this medicine out of the sight and out of reach of children.

What else should I know about ESPEROCT® and hemophilia A?

Medicines are sometimes prescribed for purposes other than those listed here. Do not use ESPEROCT® for a condition for which it is not prescribed. Do not share ESPEROCT® with other people, even if they have the same symptoms that you have.

Revised: 02/2019

For Patent Information, refer to: http://novonordisk-us.com/patients/products/product-patents.html

Manufactured by:
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd, Denmark

More detailed information is available upon request. Available by prescription only.

For information about ESPEROCT® contact:
Novo Nordisk Inc.
800 Scudders Mill Road
Plainsboro, NJ 08536, USA
1-800-727-6500

US19ESP00010 August 2019

novo nordisk®



Let's make today brilliant.

Takeda is here to support you throughout your journey and help you embrace life's possibilities. Our focus on factor treatments and educational programs, and our dedication to the bleeding disorders community, remain unchanged. And our commitment to patients, inspired by our vision for a bleed-free world, is stronger than ever.

bleedingdisorders.com

Takeda

HBDA Information

Address: 917 W Osceola Street, Wetumpka, AL 36092

Phone: (334) 478-7822

Fax: (334) 478-7824

Website: www.hbda.us

Facebook: www.facebook.com/hbda4u

Birthday Blessings

August

Amy Blair
Terrell Abrams
Jacob Weaver
Kaitlyn Weaver
Rachel Cooper-Leal
Dylan Ward
Rocisa Banks
Tikila Hawthorne
Seth Kelly
Shelia Baird
Rick Dinkins
Kristopher Lewis
Sonya Moore
Tara Gerling
Mackenzie Jones
Jeannie McLaughlin
Tim Mason
Spring Kane
Ajie Attawia
Doug Amos
Heeyeon Chung
Belita Abrams
Christian Blyden
Jason White
Taylor Barton
Kileeann Warren
Bethalyn Bailey
Makenzie Clarke
Jeannie Dickerson
LaVadre Hawthorne
Robert Bate
VaShette Davis
Garrett May
Chris Blair
Scott Vance
Odin Walls

September

Madison Kelley
Jaxson Kelley
Jared McLaughlin
Lyric Donahoo
Jessica Ward
Zachary Pressley
Mark Osborne
Larry Grammer
Brayden Cooper
NyAnnah Davis
John Masline
Erica Goss
Jaymee Vowell
Cooper Guadalupe
Vicki Jackson
Kristen Blair
Shaun Friedman
Chesca Barnett
Lee Hall
Jace McLaughlin
Amber May
Sunny Crew
Jennifer Mason
Amanda Matthews
JD Weir

October

Scott Weaver
Pat White
Caelum Walls
Nicole Lloyd
Levi McLaughlin
Luke Bradshaw
Chance Abrams
Blake Morgan
Gunner Stracener
Joshua Sorrells
Katelyn Erben
Christian Pressley
Micah Champagne
Brent Speer
Justin Clarke
Brian May
Harper Walls
Jonathan Hall
Fallon Howard
Adam Bradshaw
Jennifer Harris
Jason Kelley
Andy Hall
Tisha Ward
Ethan Fields
McKenzie Lee
Piers Smith
Brandee Cookston